Bard Financial Services Inc. Has $81,000 Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Bard Financial Services Inc. lessened its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 22.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,000 shares of the company’s stock after selling 4,250 shares during the quarter. Bard Financial Services Inc.’s holdings in ImmunityBio were worth $81,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in ImmunityBio by 42.0% during the third quarter. Vanguard Group Inc. now owns 14,675,687 shares of the company’s stock worth $24,802,000 after purchasing an additional 4,342,386 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in ImmunityBio by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 77,886 shares of the company’s stock valued at $391,000 after acquiring an additional 19,750 shares during the last quarter. SG Americas Securities LLC lifted its stake in ImmunityBio by 45.4% in the fourth quarter. SG Americas Securities LLC now owns 49,005 shares of the company’s stock valued at $246,000 after acquiring an additional 15,308 shares during the last quarter. Carlson Capital Management acquired a new stake in ImmunityBio in the fourth quarter valued at $88,000. Finally, Courier Capital LLC acquired a new stake in ImmunityBio in the fourth quarter valued at $75,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Stock Up 0.1 %

Shares of IBRX traded up $0.01 during trading hours on Friday, hitting $6.71. The company had a trading volume of 526,284 shares, compared to its average volume of 5,321,488. The firm has a market cap of $4.64 billion, a price-to-earnings ratio of -6.15 and a beta of 1.07. The business has a fifty day moving average of $6.82 and a 200-day moving average of $5.60. ImmunityBio, Inc. has a 12 month low of $1.25 and a 12 month high of $10.53.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.03 million. On average, equities analysts expect that ImmunityBio, Inc. will post -0.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Piper Sandler increased their price target on shares of ImmunityBio from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Monday, April 29th.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.